Ethyl Nipecotate CAS 5006-62-2 Assay ≥99.0% (GC) High Quality

Short Description:

Chemical Name: Ethyl Nipecotate

CAS: 5006-62-2

Appearance: Colorless to Pale Yellow Liquid

Assay: ≥99.0% (GC)

High Quality, Commercial Production

E-mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Supply with High Purity and Stable Quality
Chemical Name: Ethyl Nipecotate
CAS: 5006-62-2
High Quality, Commercial Production

Chemical Properties:

Chemical Name	Ethyl Nipecotate
Synonyms	Ethyl 3-Piperidinecarboxylate; Ethyl piperidine-3-carboxylate; 3-Piperidinecarboxylic Acid Ethyl Ester
CAS Number	5006-62-2
CAT Number	RF-PI271
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C8H15NO2
Molecular Weight	157.21
Melting Point	165.0~167.0℃
Boiling Point	102-104℃ /7 mmHg (lit.)
Density	1.012 g/mL at 25℃ (lit.)
Refractive Index	n20/D 1.460 (lit.)
Water Solubility	Miscible
Shipping Condition	Shipped Under Ambient Temperature
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Colorless to Pale Yellow Liquid
Water	≤0.50%
Single Impurity	≤0.50%
Total Impurities	≤1.0%
Heavy Metals	≤20ppm
Assay	≥99.0%
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Barrel, 25kg/Barrel, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Ethyl Nipecotate (CAS: 5006-62-2) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and Active Pharmaceutical Ingredient (API) synthesis.

Application Ethyl Nipecotate (CAS: 5006-62-2) was used in the synthesis of: α,α′-bis[3-(N,N-diethylcarbamoyl)-piperidino]-p-xylene; 2-amino-4-thiazolyl derivative of 3-(iso-propyl-3-piperidinyl)phenol;

Reactant for synthesis of: Squalene synthase inhibitors; 4-aminomethyl-7,8-dihydroxycoumarines and their crown ether derivatives; Spiroimidazolidinone NPC1L1 inhibitors; Quorum sensing modulators; Selective serotonin 5-HT6 receptor antagonists; Oxazolidinone RNA-binding agents.